AMLX Stock Analysis: Amylyx Pharmaceuticals | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 3.414m USD | 12M Return: 105.4% | US03237H1014 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 34.9M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 4.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Amylyx Pharmaceuticals (NASDAQ: AMLX) is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in Cambridge, Massachusetts. The company focuses on developing treatments for neurodegenerative diseases and endocrine conditions, with a pipeline that includes Avexitide, a first-in-class GLP-1 receptor antagonist in Phase 3 trials for post-bariatric hypoglycemia and congenital hyperinsulinism, as well as AMX0035 (in trials for Wolfram syndrome and progressive supranuclear palsy), AMX0114 for ALS, and early-stage candidates targeting rare diseases.
As a clinical-stage company, Amylyx has not yet generated commercial product revenue and its valuation depends on pipeline progress and clinical trial outcomes. Its emphasis on orphan and rare diseases positions it within a segment of the pharmaceutical sector that often benefits from extended market exclusivity and regulatory incentives, though development risk remains elevated given the early stage of most candidates.
- Avexitide Phase 3 trial data readout for post-bariatric hypoglycemia
- AMX0035 Phase 2 results in Wolfram syndrome and progressive supranuclear palsy
- GLP-1 receptor antagonist pipeline faces competition from larger pharma developers
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.48 > 0.02 and ΔFCF/TA 37.24 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.48 > 3% & CFO -126.6m > Net Income -152.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 12.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (111.2m) vs 12m ago 24.75% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 44.90%; Δ -44.90% > 0%) |
| Interest Coverage Ratio: -79.19 > 6 (EBIT TTM -150.2m / Interest Expense TTM 1.90m) |
| A: 0.89 (Total Current Assets 256.3m - Total Current Liabilities 21.1m) / Total Assets 264.6m |
| B: -3.16 (Retained Earnings -836.1m / Total Assets 264.6m) |
| C: -0.65 (EBIT TTM -150.2m / Avg Total Assets 229.6m) |
| D: 9.42 (Book Value of Equity 239.2m / Total Liabilities 25.4m) |
| Altman-Z'' = 1.02 = BB |
As of October 31, 2026, the stock is trading at USD 28.86 with a total of 989,520 shares traded. Over the past week, the price has changed by +6.10%, over one month by -1.43%, over three months by +39.08% and over the past year by +105.41%.
Current recommended Stop Loss: 25.00 (which is 13.4% or 2.8 ATR below the current price).
Amylyx Pharmaceuticals has received a consensus analysts rating of 4.83. Therefore, it is recommended to buy AMLX.
- StrongBuy: 11
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 43 | 49% |
P/E Forward = 2.7739
P/S = 0.6625
P/B = 17.3182
Revenue TTM = 0.0 USD
EBIT TTM = -150.2m USD
EBITDA TTM = -149.8m USD
Long Term Debt = 4.25m USD (estimated: total debt 5.25m - short term 1.01m)
Short Term Debt = 1.01m USD (from shortTermDebt, last quarter)
Debt = 5.25m USD (from shortLongTermDebtTotal, last quarter) (leases 5.25m already included)
Net Debt = -245.5m USD (calculated: Debt 5.25m - CCE 250.8m)
Enterprise Value = 3.17b USD (3.41b + Debt 5.25m - CCE 250.8m)
Interest Coverage Ratio = -79.19 (Ebit TTM -150.2m / Interest Expense TTM 1.90m)
EV/FCF = -25.00x (Enterprise Value 3.17b / FCF TTM -126.7m)
FCF Yield = -4.00% (FCF TTM -126.7m / Enterprise Value 3.17b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 525k) / Revenue TTM)
Tobins Q-Ratio = 11.98 (Enterprise Value 3.17b / Total Assets 264.6m)
Interest Expense / Debt = 36.08% (Interest Expense 1.90m / Debt 5.25m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -118.6m (EBIT -150.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 12.12 (Total Current Assets 256.3m / Total Current Liabilities 21.1m)
Debt / Equity = 0.02 (Debt 5.25m / totalStockholderEquity, last quarter 239.2m)
Debt / EBITDA = 1.64 (negative EBITDA) (Net Debt -245.5m / EBITDA -149.8m)
Debt / FCF = 1.94 (negative FCF - burning cash) (Net Debt -245.5m / FCF TTM -126.7m)
Total Stockholder Equity = 287.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -66.25% (Net Income -152.1m / Total Assets 264.6m)
RoE = -52.92% (Net Income TTM -152.1m / Total Stockholder Equity 287.4m)
RoCE = -51.48% (EBIT -150.2m / Capital Employed (Equity 287.4m + L.T.Debt 4.25m))
RoIC = -48.53% (negative operating profit) (NOPAT -118.6m / Invested Capital 244.4m)
WACC = 6.37% (E(3.41b)/V(3.42b) * Re(6.34%) + D(5.25m)/V(3.42b) * Rd(36.08%) * (1-Tc(0.21)))
Discount Rate = 6.34% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 96.01 | Cagr: 24.55%
[DCF] Fair Price = unknown (Cash Flow -126.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.29 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.37 | Chg30d=+0.85% | Revisions=-22% | Analysts=8
EPS current Year (2026-12-31): EPS=-1.48 | Chg30d=+0.87% | Revisions=-22% | GrowthEPS=+3.0% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.09 | Chg30d=+5.56% | Revisions=+0% | GrowthEPS=+26.5% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -19% (up=7, down=11)